Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Collen

Showing results (611-620 of 715) with videos related to

Pageof 72
Sort By:
Thrombosis and Haemostasis|August 30, 1985
Increased PA-inhibitor levels in the postoperative period--no cause-effect relation with increased cortisolM F Aillaud, I Juhan-Vague, M C Alessi, et al.
Journal of Thrombosis and Haemostasis : JTH|February 8, 2006
Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaquesP Rossignol, A Luttun, J L Martin-Ventura, et al.
Arteriosclerosis and Thrombosis : a Journal of Vascular Biology|December 1, 1993
A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboonsC Kohmura, H K Gold, T Yasuda, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 23, 2001
Circulating oxidized LDL is a useful marker for identifying patients with coronary artery diseaseP Holvoet, A Mertens, P Verhamme, et al.
Thrombosis and Haemostasis|February 3, 1992
Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell lineH R Lijnen, P D Webb, B Van Hoef, et al.
Journal of the American College of Cardiology|April 1, 1991
Bleeding time prolongation and bleeding during infusion of recombinant tissue-type plasminogen activator in dogs: potentiation by aspirin and reversal with aprotininH D Garabedian, H K Gold, R C Leinbach, et al.
Coronary Artery Disease|March 1, 1995
Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogsL Jun, J Arnout, P Vanhove, et al.
Journal of the American College of Cardiology|July 1, 1986
Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasisW Flameng, J Vanhaecke, D C Stump, et al.
The Journal of Biological Chemistry|October 25, 1990
Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectinK T Preissner, J Grulich-Henn, H J Ehrlich, et al.
Circulation|February 1, 1989
Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosisA A Ziskind, H K Gold, T Yasuda, et al.
Pageof 72

Showing results (611-620 of 715) with videos related to

Sort By:
Pageof 72
Thrombosis and Haemostasis|August 30, 1985
Increased PA-inhibitor levels in the postoperative period--no cause-effect relation with increased cortisolM F Aillaud, I Juhan-Vague, M C Alessi, et al.
Journal of Thrombosis and Haemostasis : JTH|February 8, 2006
Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaquesP Rossignol, A Luttun, J L Martin-Ventura, et al.
Arteriosclerosis and Thrombosis : a Journal of Vascular Biology|December 1, 1993
A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboonsC Kohmura, H K Gold, T Yasuda, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 23, 2001
Circulating oxidized LDL is a useful marker for identifying patients with coronary artery diseaseP Holvoet, A Mertens, P Verhamme, et al.
Thrombosis and Haemostasis|February 3, 1992
Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell lineH R Lijnen, P D Webb, B Van Hoef, et al.
Journal of the American College of Cardiology|April 1, 1991
Bleeding time prolongation and bleeding during infusion of recombinant tissue-type plasminogen activator in dogs: potentiation by aspirin and reversal with aprotininH D Garabedian, H K Gold, R C Leinbach, et al.
Coronary Artery Disease|March 1, 1995
Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogsL Jun, J Arnout, P Vanhove, et al.
Journal of the American College of Cardiology|July 1, 1986
Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasisW Flameng, J Vanhaecke, D C Stump, et al.
The Journal of Biological Chemistry|October 25, 1990
Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectinK T Preissner, J Grulich-Henn, H J Ehrlich, et al.
Circulation|February 1, 1989
Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosisA A Ziskind, H K Gold, T Yasuda, et al.
Pageof 72